Authors: | Dang, N. H.; Ogura, M.; Castaigne, S.; Fayad, L. E.; Jerkeman, M.; Radford, J.; Pezzutto, A.; Bondarenko, I.; Stewart, D. A.; Shnaidman, M.; Sullivan, S.; Vandendries, E.; Tobinai, K.; Ramchandren, R.; Hamlin, P. A.; Giné, E.; Ando, K. |
Article Title: | Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma |
Keywords: | adult; controlled study; protein expression; treatment response; major clinical study; overall survival; constipation; fatigue; neutropenia; cancer recurrence; diarrhea; drug efficacy; drug safety; drug withdrawal; side effect; gemcitabine; rituximab; letter; progression free survival; anemia; leukopenia; nausea; randomized controlled trial; thrombocytopenia; vomiting; cohort analysis; bendamustine; alanine aminotransferase blood level; aspartate aminotransferase blood level; coughing; febrile neutropenia; fever; gamma glutamyl transferase blood level; lymphocytopenia; pneumonia; alanine aminotransferase; alkaline phosphatase; aspartate aminotransferase; nonhodgkin lymphoma; alkaline phosphatase blood level; hyperbilirubinemia; phase 3 clinical trial; gamma glutamyltransferase; treatment withdrawal; cd22 antigen; decreased appetite; septicemia; inotuzumab ozogamicin; diffuse large b cell lymphoma; antibody-drug conjugate; human; priority journal; b-cell non-hodgkin lymphoma; cd22+ |
Journal Title: | British Journal of Haematology |
Volume: | 182 |
Issue: | 4 |
ISSN: | 0007-1048 |
Publisher: | John Wiley & Sons |
Date Published: | 2018-08-01 |
Start Page: | 583 |
End Page: | 586 |
Language: | English |
DOI: | 10.1111/bjh.14820 |
PROVIDER: | scopus |
PUBMED: | 28677896 |
PMCID: | PMC6200343 |
DOI/URL: | |
Notes: | Letter -- Export Date: 4 September 2018 -- Source: Scopus |